ArriVent BioPharma, Inc. AVBP Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s total current liabilities?
- ArriVent BioPharma, Inc. (AVBP) reported total current liabilities of $25M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s total current liabilities changed year-over-year?
- ArriVent BioPharma, Inc.'s total current liabilities increased by 93.0% year-over-year, from $12.95M to $25M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s total current liabilities?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s total current liabilities has grown at a 49.4% compound annual growth rate (CAGR), from $11.62M to $25.95M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.